Dexedrine is a brand name for dextroamphetamine sulfate, one of the oldest and most potent prescription stimulants still in clinical use. It contains only the d-isomer of amphetamine, which is the more pharmacologically active half of the amphetamine molecule, making it roughly twice as potent milligram-for-milligram as racemic amphetamine at boosting dopamine and norepinephrine in the brain. Approved primarily for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy, Dexedrine occupies a somewhat unusual position in modern psychiatry: it predates nearly every other ADHD medication on the market, yet it remains less widely prescribed than newer formulations like Adderall and Vyvanse that are built around the same active compound.
What Dexedrine Does in the Brain
Dextroamphetamine works differently from most psychiatric medications. Rather than blocking the reuptake of neurotransmitters (the way SSRIs hold serotonin in the synapse), it actively pushes dopamine and norepinephrine out of nerve terminals. The drug enters the presynaptic neuron and binds to a transporter called VMAT2, which normally packages dopamine into storage vesicles. By disrupting that packaging, dextroamphetamine causes dopamine to accumulate in the cell’s interior. It also activates an intracellular receptor called TAAR1, which promotes the outward flow of dopamine through the dopamine transporter. The net result is a flood of dopamine and norepinephrine into the synaptic space, particularly in the prefrontal cortex and striatum.1Journal of Clinical Investigation. CNS-targeting pharmacological interventions for the metabolic syndrome
This mechanism explains both the drug’s therapeutic effects and its potential for misuse. In people with ADHD, the prefrontal cortex tends to be underactive, and the dopamine boost helps restore focus, impulse control, and the ability to sustain attention on unrewarding tasks. The same dopamine surge, though, is what makes amphetamines feel euphoric at higher doses and what activates reward pathways linked to addiction.2Psychiatric Clinics of North America. USE OF STIMULANTS IN THE MEDICALLY ILL – Section: TOLERANCE, ABUSE, AND ADDICTION
Approved Medical Uses
Dexedrine has two primary FDA-approved indications. The first and most common is ADHD, where stimulants as a class produce large treatment effects. Studies of FDA-approved ADHD medications, including dextroamphetamine, have found effect sizes ranging from about 0.7 to 1.5 on standardized symptom scales, which is notably strong compared to most psychiatric treatments.3PubMed. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults In head-to-head trials, dextroamphetamine has performed comparably to other stimulants, with significantly improved scores on ADHD symptom checklists relative to placebo.4PubMed Central. Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects
The second approved use is narcolepsy, a sleep disorder marked by uncontrollable daytime sleepiness and, in some cases, sudden loss of muscle tone. In trials comparing stimulants for narcolepsy, dextroamphetamine and methylphenidate were the only drugs that brought wakefulness scores to roughly 70% of normal levels, outperforming modafinil and pemoline on that measure.5PubMed Central. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy Despite that track record, modafinil and its derivatives have largely replaced amphetamines as first-line narcolepsy treatment, mainly because they carry less abuse potential and fewer cardiovascular effects.
How Dexedrine Compares to Adderall and Vyvanse
One of the most common questions people have is how Dexedrine differs from the other amphetamine-based medications. The differences are real but more subtle than many patients expect.
Adderall is a mixture of four amphetamine salts, roughly 75% dextroamphetamine and 25% levoamphetamine. That levoamphetamine component is weaker at boosting dopamine but has a stronger peripheral effect on norepinephrine, which is why some patients report that Adderall feels “pushier” physically. In a controlled trial of mixed amphetamine salts (Adderall) in adults with ADHD, about 70% of participants showed meaningful symptom improvement, compared to 7% on placebo.6JAMA Network. Efficacy of a Mixed Amphetamine Salts Compound in Adults With Attention-Deficit/Hyperactivity Disorder Dexedrine, being pure d-amphetamine, lacks that levoamphetamine component entirely. Some clinicians prefer it for patients who are sensitive to peripheral stimulant effects like jitteriness or elevated blood pressure, since the l-isomer contributes more to those symptoms.
Vyvanse (lisdexamfetamine) is a prodrug: it is chemically inactive until enzymes in the blood cleave off a lysine amino acid, releasing plain dextroamphetamine. The conversion step creates a built-in delay. Compared to immediate-release dextroamphetamine, Vyvanse reaches peak blood levels about an hour later and has a lower, more gradual peak concentration, with less variability from dose to dose and person to person.7PubMed Central. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy Total exposure over the day, however, ends up about the same.8PubMed Central. Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects The practical upshot is that Vyvanse has a smoother ride and is harder to abuse by snorting or injecting, since those routes cannot speed up the enzymatic conversion. The active drug at the end of the process, though, is the same dextroamphetamine that Dexedrine delivers directly.
Immediate-Release Versus Extended-Release Formulations
Dexedrine has historically been available in both immediate-release (IR) tablets and sustained-release (Spansule) capsules. The pharmacokinetic differences matter for daily life. Immediate-release dextroamphetamine peaks in the blood at roughly one and a half to two hours, and when taken twice daily (which is the standard dosing), it produces two distinct peaks over the course of a day. Modified-release formulations, by contrast, are designed to deliver a plateau of drug levels lasting about four to six hours during which blood concentrations stay above 75% of their peak. Despite the different release profiles, the drug’s elimination half-life is about the same either way: around 10 to 11 hours.9PubMed Central. Pharmacokinetics of a Modified-Release Dexamphetamine Sulfate Formulation Following Single and Multiple Dosing in Healthy Adults
That half-life is worth knowing because it affects sleep. Even if you take your last dose at noon, meaningful amounts of dextroamphetamine will still be circulating at bedtime. Many patients find they need to experiment with dosing times, and clinicians often suggest moving the last dose earlier in the day if insomnia becomes a problem.
Cardiovascular Effects
Every stimulant carries warnings about cardiovascular risk, and Dexedrine is no exception. In a military study measuring the effects of operationally relevant doses (three 10 mg doses over a day), researchers observed persistent elevations in heart rate starting about two hours after the second dose. Systolic blood pressure rose as well, though the timing differed between men and women. Diastolic blood pressure showed a sustained increase in both groups. None of these changes led to clinical problems during the study.10Military Medicine. Effects of Operationally Effective Doses of Dextroamphetamine on Heart Rates and Blood Pressures of Army Aviators
The larger question is whether long-term stimulant use increases the risk of heart attacks, strokes, or arrhythmias. In younger populations, available data on dextroamphetamine have shown essentially no significant cardiovascular changes in children and adolescents treated for ADHD.11PubMed. Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder In older adults, a study comparing veterans who took amphetamine/dextroamphetamine with those who took methylphenidate found no difference in major cardiovascular events between the two groups.12PubMed. Cardiovascular Safety of Amphetamine/Dextroamphetamine versus Methylphenidate in Older Adults That said, the study populations were modest in size, and patients with serious pre-existing heart disease are typically excluded from these drugs in the first place. Anyone with a history of structural heart problems, uncontrolled high blood pressure, or a personal or family history of sudden cardiac death should have a thorough evaluation before starting any stimulant.
Growth Concerns in Children
Parents often worry that stimulants will stunt their child’s growth, and there is some basis for that concern. Stimulants suppress appetite, and across multiple studies the height shortfall associated with stimulant use amounts to roughly one centimeter per year during the first three years of treatment.13Activitas Nervosa Superior. Effect of Stimulants on Growth of ADHD Children: A Critical Review Weight loss tends to be most noticeable in the first few months and is more pronounced in younger, pre-pubertal children. However, a two-year study tracking children on various stimulants found that while weight dipped initially, the changes did not reach clinical significance over the long run, and there was no lasting impact on height. BMI growth stayed within normal limits throughout.14Research in Developmental Disabilities. Effects of long-term psychostimulant medication on growth of children with ADHD
The practical takeaway is that growth should be monitored, especially in the first year or two, but most children ultimately catch up. Some clinicians recommend “drug holidays” over the summer to allow appetite and growth to rebound, though this practice is debated and not universally endorsed.
Psychiatric Side Effects at Higher Doses
One risk that deserves plain language is the link between prescription amphetamines and psychosis or mania. A large case-control study found that people who had filled a prescription for amphetamines in the past month had roughly two and a half times the odds of experiencing psychosis or mania compared to non-users. The risk was dose-dependent: at doses above 30 mg of dextroamphetamine equivalents per day, the odds were more than five times higher.15PubMed Central. Risk of Incident Psychosis and Mania With Prescription Amphetamines
This does not mean that everyone on Dexedrine is at serious risk of losing touch with reality. The absolute incidence is still low, and the vast majority of patients on therapeutic doses never experience psychotic symptoms. But the risk climbs with dose, which is one reason clinicians start low and titrate gradually. People with a personal or family history of bipolar disorder or psychotic episodes should discuss these findings with their prescriber, because the threshold for triggering an episode may be lower.
Does Dexedrine Actually Improve Cognition in People Without ADHD?
College students and professionals sometimes seek dextroamphetamine for cognitive enhancement, expecting it to sharpen focus and memory. The research paints a more complicated picture. A study using brain imaging found that dextroamphetamine improved working-memory performance only in participants who had relatively low working-memory capacity at baseline. In people who already performed well, the drug actually worsened their scores. Brain activation in the prefrontal cortex was higher in the group whose performance deteriorated, suggesting the drug pushed an already-optimized system past its sweet spot.16PubMed. Effects of dextroamphetamine on cognitive performance and cortical activation
This finding aligns with an observation that dates back to the early history of amphetamine research. Military testing during the 1930s and 1940s found that the cognitive benefits of amphetamines were largely subjective: users felt more alert and capable, but objective measures of attention and decision-making did not always confirm that impression. The mood-elevating effect was often the main driver of the perceived improvement.17PubMed. Amphetamine-Type Stimulants: The Early History of Their Medical and Non-Medical Uses In other words, dextroamphetamine reliably makes you feel sharper, but whether you actually are sharper depends on where you started.
Urine pH and Drug Interactions
Dextroamphetamine is unusual among psychiatric medications in that its clearance from the body is heavily influenced by urine pH. In acidic urine, the drug is ionized in the kidney tubules and gets excreted quickly; in alkaline urine, more of the drug is reabsorbed back into the bloodstream, extending its duration and raising blood levels.18PubMed Central. Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine This has real-world consequences. Taking sodium bicarbonate (baking soda) or certain antacids can alkalinize urine and dramatically increase dextroamphetamine exposure, while high-dose vitamin C or cranberry juice does the opposite.
The same pH sensitivity applies to Vyvanse, since the active drug released from lisdexamfetamine is dextroamphetamine. Alkalizing agents can prolong its effects as well.19PubMed. Comparative pharmacology and abuse potential of oral dexamphetamine and lisdexamfetamine-A literature review Patients should let their prescriber know about any regular antacid use or high-dose vitamin C supplementation, because these seemingly harmless over-the-counter products can meaningfully alter how much active stimulant ends up in your system.
Pregnancy and Dexedrine
Whether to continue a stimulant during pregnancy is one of the harder decisions women with ADHD face. A large multi-cohort study looked at whether amphetamine/dextroamphetamine exposure during pregnancy raised the risk of neurodevelopmental disorders in children, including autism and ADHD. The raw numbers looked alarming: unadjusted analyses showed roughly double the risk of autism and ADHD in exposed children. But after adjusting for the mother’s own ADHD diagnosis and other confounders, those associations vanished. Exposure during pregnancy was not associated with any of the three neurodevelopmental outcomes studied.20JAMA Psychiatry. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children
When the analysis was restricted to mothers with a diagnosed ADHD condition, there was still no increase in risk. One signal that resisted adjustment was a modest association between late-pregnancy amphetamine exposure and autism in the comparison group of women who had stopped the drug before pregnancy, but that signal came from a single data source and was not replicated across cohorts. The overall picture suggests that the underlying maternal ADHD, rather than the drug itself, accounts for much of the apparent risk seen in crude analyses. Still, most guidelines recommend discussing the decision with a specialist, since other pregnancy concerns like blood-pressure changes and reduced appetite also factor in.
Tolerance and Long-Term Questions
A concern that comes up less often in prescribing conversations than it probably should is whether stimulants lose their effectiveness over years of use. There is limited long-term efficacy data for any stimulant, and some clinicians have raised the possibility that tolerance develops gradually, sometimes leading to a paradoxical worsening of ADHD symptoms over time.21PubMed Central. The Dopamine Dilemma-Part II: Could Stimulants Cause Tolerance, Dependence, and Paradoxical Decompensation? The mechanisms proposed for this include downregulation of dopamine receptors and changes in transporter density. Animal studies have shown that even doses mimicking therapeutic use can alter dopamine-transporter levels in the striatum, and brain-imaging studies in humans have found changes in transporter availability with stimulant treatment.22PubMed. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD
Whether these neurobiological changes translate into clinically meaningful tolerance in most patients is genuinely unclear. Many adults report stable benefits over years of treatment at the same dose. Others find that doses creep upward over time or that the drug seems less effective. When patients feel their medication has stopped working, the answer is not always to increase the dose. Periodic reassessment, including structured drug holidays, can help distinguish true pharmacological tolerance from changes in life circumstances, sleep habits, or evolving symptom profiles.
Supply Shortages
If you have been prescribed Dexedrine or any amphetamine-based medication in recent years, you may have encountered empty shelves at the pharmacy. Shortages of prescription amphetamine derivatives have been a recurring problem for over two decades. Between 2001 and 2023, there were 26 verified shortages affecting this drug class, with the worst years being 2012, 2013, 2015, and 2023. Resolved shortages lasted an average of about 21 months, and some dragged on for over five years.23PubMed Central. Drug Shortages for Prescription Amphetamine Derivatives
The causes are layered. Amphetamines are Schedule II controlled substances, meaning the DEA sets annual production quotas. When demand rises sharply, as it did during and after the pandemic, manufacturers cannot simply ramp up production without regulatory approval. Raw-material supply chain issues, manufacturing delays, and a surge in new ADHD diagnoses among adults have all contributed. For patients, the practical advice is to keep communication open with your pharmacy, request that they order your specific formulation in advance, and ask your prescriber about clinically equivalent alternatives if your usual medication is unavailable. Switching between dextroamphetamine products is generally straightforward from a pharmacological standpoint, though individual responses can vary enough that any switch warrants close follow-up.
Off-Label Use in Treatment-Resistant Depression
Dextroamphetamine occasionally surfaces as an augmentation strategy for depression that has not responded to standard antidepressants. The idea is not new. Amphetamines were widely used as antidepressants in the 1940s before being displaced by tricyclics and, later, SSRIs.24PubMed. Amphetamine-Type Stimulants: The Early History of Their Medical and Non-Medical Uses Today, some psychiatrists will add a low-dose amphetamine to an existing antidepressant regimen when patients have exhausted other options, including therapy, multiple medication trials, and even transcranial magnetic stimulation. Case reports have documented significant improvement in patients for whom nothing else had worked.25PubMed Central. Dextroamphetamine-Amphetamine Augmentation in the Treatment of Treatment-Resistant Depression
This use remains off-label and supported mainly by case reports and small studies rather than randomized controlled trials. The risk-benefit calculus is tricky: the mood-elevating properties that make amphetamines attractive for depression overlap with the properties that carry abuse potential. Most clinicians reserve this approach for patients under close monitoring who have genuinely run out of better-studied options.